<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011711</url>
  </required_header>
  <id_info>
    <org_study_id>2013H0235</org_study_id>
    <secondary_id>R01HD072663</secondary_id>
    <nct_id>NCT02011711</nct_id>
  </id_info>
  <brief_title>Modulation of Immunity by Hormonal Contraceptives</brief_title>
  <official_title>Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas L. Cherpes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study to determine if hormonal contraceptive use effects cells that fight infection
      (i.e., immune cells).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Feminization of the HIV pandemic is impetus for better understanding of the risk factors
      promoting male to female sexual transmission. One putative risk factor is hormonal
      contraceptive use. Our laboratory recently reported that dendritic cell activation,
      virus-specific T cell expansion, and memory T cell development were impaired among female
      mice administered depot-medroxyprogesterone acetate (DMPA) prior to viral infection of
      mucosal tissue, and we now are enrolling women into a clinical investigation exploring the
      immunomodulatory effects of several common hormonal contraceptive forms. Completion of this
      research will provide important comparative evaluation of the capacity of these drugs to
      modulate host defenses combating genital tract infection, eventually supplying healthcare
      providers more informed recommendations regarding appropriate hormonal contraceptive choices
      among women at risk for acquisition of HIV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ectocervical permeability</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Mirena</arm_group_label>
    <description>Women interested in beginning use of Mirena</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depot-medroxyprogesterone acetate</arm_group_label>
    <description>Women interested in beginning use of depot-medroxyprogesterone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Contraception</arm_group_label>
    <description>Women interested in beginning use of oral contraception</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women seeking to initiate use of an oral contraceptive, depot-medroxyprogesterone acetate,
        or Mirena.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  not pregnant

          -  regular menstrual cycle

        Exclusion Criteria:

          -  use of oral contraceptive or Mirena in 3 months prior to enrollment

          -  use of depot-medroxyprogesterone acetate in 6 months prior to enrollment

          -  diagnosis of sexually transmitted infection in 30 days prior to enrollment

          -  history of cervical malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Cherpes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edwards Building</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vicetti Miguel RD, Hendricks RL, Aguirre AJ, Melan MA, Harvey SA, Terry-Allison T, St Leger AJ, Thomson AW, Cherpes TL. Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. J Immunol. 2012 Oct 1;189(7):3449-61. Epub 2012 Aug 31.</citation>
    <PMID>22942424</PMID>
  </reference>
  <reference>
    <citation>Quispe Calla NE, Vicetti Miguel RD, Mei A, Fan S, Gilmore JR, Cherpes TL. Dendritic cell function and pathogen-specific T cell immunity are inhibited in mice administered levonorgestrel prior to intranasal Chlamydia trachomatis infection. Sci Rep. 2016 Nov 28;6:37723. doi: 10.1038/srep37723.</citation>
    <PMID>27892938</PMID>
  </reference>
  <results_reference>
    <citation>Quispe Calla NE, Ghonime MG, Cherpes TL, Vicetti Miguel RD. Medroxyprogesterone acetate impairs human dendritic cell activation and function. Hum Reprod. 2015 May;30(5):1169-77. doi: 10.1093/humrep/dev035. Epub 2015 Mar 3.</citation>
    <PMID>25740884</PMID>
  </results_reference>
  <results_reference>
    <citation>Quispe Calla NE, Vicetti Miguel RD, Boyaka PN, Hall-Stoodley L, Kaur B, Trout W, Pavelko SD, Cherpes TL. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. Mucosal Immunol. 2016 Nov;9(6):1571-1583. doi: 10.1038/mi.2016.22. Epub 2016 Mar 23.</citation>
    <PMID>27007679</PMID>
  </results_reference>
  <results_reference>
    <citation>Quispe Calla NE, Vicetti Miguel RD, Trout W, Cherpes TL. HIV and Hormonal Contraception: Bench and Bedside. J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e85-e86. doi: 10.1097/QAI.0000000000001174.</citation>
    <PMID>27599006</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Thomas L. Cherpes</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

